Remarks

Claims 1, 5, 7 and 11 have been amended. The claims as amended correspond to Group II as identified by the Office. Claims 1-14 remain in the application.

Claims 1, 5, 7 and 11 have been amended to delete the reference to the FLJ21425 gene and its primers SEQ ID NOS. 1 and 2. This amendment is supported in the specification, for example, by claims 1-14 as originally filed.

In addition, the Office indicated that Applicants should elect one of the compounds listed in Claim 14, corticosteroids, retinoic acids, interleukin 10, vitamin D3, and mifepristone. Applicants elect the species of the use of mifepristone to treat a patient in which a polymorphism of a CSFIR gene associated with a genetic predisposition for inflammatory bowel disease has been detected. Since this is a method of treatment for the patient identified in Claim 7, Applicants believe that Claims 7-14, as amended, read on the elected species. Claims 7 and 13 are generic claims. Upon allowance of a generic claim, then Applicants are entitled to consideration of claims to the additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided in 37 C.F.R. 1.141.

Conclusion

Allowance of Claims 1-14 at an early date is respectfully requested.

Respectfully submitted,

Bonnie J. Davis

Registration No. 41,699 Taylor, Porter

P.O. Box 2471

Baton Rouge, Louisiana 70821

(225) 387-3221

December 14, 2007